Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology ...

INOVIO’s DNA medicines platform combines proprietary DNA plasmid design with CELLECTRA delivery technology, enabling cells to ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

Investing.com -- 4basebio PLC (AIM:4BB) stock surged 6.9% on Monday after announcing that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II clinical trials using the ...

Cambridge, UK, 27 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products announces that, following Investigational New Drug (IND) approval from the FDA, a ...

Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial ...

The U.S. IND CDMO market offers growth via extensive pipelines in oncology and rare diseases, driven by technological advancements, outsourcing trends, regulatory efficiencies, and modular GMP ...

The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to ...

BioCina, a leading pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dr. Thomas Broudy has been appointed as Chief Executive Officer to lead the company's ...

A new way to deliver protective antibodies against COVID-19 was tested in a Phase I clinical trial. Instead of injecting ...